GOOD JOB Through Crash A Unique Perspective on Chery's Crash Test Lab
WUHU, China, Dec. 12, 2024 /PRNewswire/ -- Recently, Chery Auto released an unconventional and engaging video that takes viewers on an intriguing journey through its cutting-edge crash test lab. Through the unique perspective of a newly "hired"...
Global Times: China's modern thoughts inherited wisdom of ancient strategy for sustainable peace
BEIJING, Dec. 12, 2024 /PRNewswire/ -- Sun Tzu, one of the greatest strategists in human history, lived during China's Spring and Autumn period (770-476 BC). His book The Art of War remains one of the world's most influential works of military...
Infor's Industry Research Study Reveals Value Drivers Shared by Highly Productive Organizations
Flagship global research reveals how high-performing organizations achieve true value creation from their technology investments NEW YORK, Dec. 12, 2024 /PRNewswire/ -- Infor, the industry cloud complete company, has released the results of its...
MiniTool Released MovieMaker 8.0 with Multi-Track Video Editing Features
VANCOUVER, BC, Dec. 11, 2024 /PRNewswire/ -- MiniTool Software Limited has released the latest version of its video editing tool, MiniTool MovieMaker 8.0. The completely new edition rebuilds its timeline by supporting multi-track editing to optimize...
Live from ASH 2024 | Oral Report Features Encouraging Data of Ascentage Pharma's Bcl-2 Inhibitor Lisaftoclax in R/R MM, Including a Median PFS Over 9 Months
ROCKVILLE, Md. and SUZHOU, China, Dec. 10, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing, and commercializing therapies to address global unmet medical needs primarily for...
Live from ASH 2024 | Ascentage Pharma's Bcl-2 Inhibitor Lisaftoclax in Combinations Demonstrates Potential Clinical Benefit in Patients with Prior Exposure to Venetoclax
ROCKVILLE, Md. and SUZHOU, China, Dec. 10, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing, and commercializing therapies to address global unmet medical needs primarily for...
The new battleground for commercial card providers: Rewards and flexibility, Ascenda report reveals
Fintech disruption and evolving rewards reshape business spending landscape NEW YORK, Dec. 10, 2024 /PRNewswire/ -- Ascenda, the global leader in loyalty as a service, today released its 2024 State of Loyalty: Commercial Cards report. The report...
Live from ASH 2024 | First Dataset of Olverembatinib as Second-Line Therapy in Patients with Non-T315I-Mutant CP-CML Presented in Oral Report
ROCKVILLE, Md. and SUZHOU, China, Dec. 10, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing, and commercializing therapies to address global unmet medical needs primarily for...
Live from ASH 2024 | 1.5-Year Follow-Up Data from a Global Study of Olverembatinib Reaffirms Potential in Overcoming Resistance/Intolerance to Ponatinib or Asciminib
ROCKVILLE, Md. and SUZHOU, China, Dec. 10, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing, and commercializing therapies to address global unmet medical needs primarily for...
QS World University Rankings: Sustainability 2025
LONDON, Dec. 10, 2024 /PRNewswire/ -- QS Quacquarelli Symonds, global higher education experts, released the third edition of the QS World University Rankings: Sustainability, showcasing over 1,740 universities from 107 locations. The University of...